IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, who has left the company to pursue other opportunities.
Dr. Egberts has more than 25 years of executive experience in the pharmaceutical and medical device sectors. He served most recently as CEO of the specialty pharmaceutical company OctoPlus (Euronext; OCTO), which was acquired in 2013 by India-based Dr. Reddy’s Laboratories Ltd. Prior to OctoPlus, he held business development and general management positions of increasing responsibility at McKinsey & Co., Merck, Johnson & Johnson and Mölnlycke Health Care and served as CEO of Novadel Pharmaceuticals, Inc. Dr. Egberts also served as Operating Partner/Senior Advisor Healthcare for 3i, the private equity firm. He graduated from Erasmus University Medical School in the Netherlands and pursued his clinical training at Harvard Medical School. He obtained his MBA from Stanford after which he worked as a management consultant at McKinsey & Co.
“I’m pleased to be able to further serve Agendia’s growing number of physician customers, their patients and my fellow shareholders,” Dr. Egberts said. “I’m firmly committed to leading the company and laying the foundation for the next level of success, as we expand the sales of MammaPrint, BluePrint and our other molecular tests, and as we continue to bring the benefits of our tests to patients around the world.”
Dr. Egberts noted that Agendia’s molecular diagnostic technology for breast cancer has recently been featured in a number of prominent scientific studies, journal articles and peer-reviewed presentations, including:
- Publication of a large multi-site study in the Annals of Surgical Oncology, validating the MammaPrint and BluePrint tests’ ability to identify molecular subtypes and better guide preoperative treatment
- Presentation of the first independent study to document how MammaPrint and BluePrint together eliminate the uncertainty of “intermediate” results for risk of breast cancer recurrence, an uncertainty that is inherent in competing technologies.
- Progress in the I-SPY 2 clinical trial involving the US FDA, NIH, leading academic cancer centers and pharmaceutical companies, for which MammaPrint was selected the biomarker of choice.
“Having achieved these recent milestones, Agendia is well positioned to continue its growth trajectory and provide a highly accurate and actionable molecular diagnostics platform for the oncology community and other stakeholders,” Dr Egberts said.
Agendia is a privately owned, leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome. This includes FDA-cleared MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay back by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the I-SPY 2 and the MINDACT trials. For more information, visitwww.agendia.com.